Talphera (NASDAQ:TLPH) Now Covered by Analysts at Rodman & Renshaw

Rodman & Renshaw began coverage on shares of Talphera (NASDAQ:TLPH) in a research report report published on Tuesday, Marketbeat.com reports. The firm issued a buy rating and a $4.00 target price on the stock.

Several other research firms have also recently issued reports on TLPH. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price target on shares of Talphera in a research note on Tuesday, January 21st. Maxim Group upgraded shares of Talphera to a “strong-buy” rating in a research report on Friday, November 8th.

Talphera Stock Up 1.1 %

Shares of NASDAQ:TLPH opened at $0.73 on Tuesday. The company has a market capitalization of $12.40 million, a P/E ratio of -1.06 and a beta of 0.28. Talphera has a 52-week low of $0.50 and a 52-week high of $1.61. The stock’s fifty day simple moving average is $0.65 and its 200-day simple moving average is $0.81.

Institutional Trading of Talphera

A hedge fund recently bought a new stake in Talphera stock. Rosalind Advisors Inc. bought a new stake in Talphera, Inc. (NASDAQ:TLPH) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 758,966 shares of the company’s stock, valued at approximately $650,000. Talphera accounts for about 0.4% of Rosalind Advisors Inc.’s investment portfolio, making the stock its 25th biggest holding. Rosalind Advisors Inc. owned about 4.47% of Talphera as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 37.67% of the company’s stock.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.